Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-06-12
2010-02-02
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S460000
Reexamination Certificate
active
07655694
ABSTRACT:
The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4′,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.
REFERENCES:
patent: 5824702 (1998-10-01), Wei
patent: 5994409 (1999-11-01), Stogniew et al.
patent: 6071956 (2000-06-01), Slepian et al.
patent: 6399655 (2002-06-01), de Juan, Jr.
patent: 6426362 (2002-07-01), Miller et al.
patent: 6524832 (2003-02-01), Kufe et al.
patent: 6544566 (2003-04-01), Waggle et al.
patent: 2337152 (2000-02-01), None
patent: WO 01/95901 (2001-12-01), None
Li et al. Soybean isoflavones reduce experimental metastasis in mice, J of Nutrition, 1999, 129:1075-1078.
Hargreaves et al. (The J of Clinical Endocrinology and Metabolism, 84, 11, 1999, p. 4017-4023).
Weiss et al. (Annals of the NY Academy of Sciences, Jan. 2000, 899, p. 44-60).
Devi et al. (The British J of Radiology, 1998, p. 782-784).
Hakov'a et al. (J Pharm Pharmacol. Oct. 1993 45(10) 910-2.
Fotsis et al. (J Nutr, 1995, p. 790S-797S).
Booth et al. (British J of Cancer, 1999, 80(10), 1550-57).
Traganos et al. (Cancer Research, 52, 6200-6208, 1992).
Casarett (Radiation Biology, 1968, Chap 10, p. 1-7).
Akimoto et al. (Int J Rad Oncology, Biol. Phys. vol. 50, 1, 195-201, 2001).
Guidance for Industry (FDA), Jul. 2005, 1-27.
Dauer and Coon (Flavonoids on Xray Mortality, p. 702-707).
Ravindranath et al. (Adv .in Exptl Medicine and Biology, 2004, 546, 121-65).
Papazisis et al (Cancer Letters, 160, 2000, 107-113).
Haley and Mann (Ineffectiveness of flavanoids in Radiation, p. 665-667).
Hilmann et al. (Clinical Cancer Research, 7, 2001, 382-390).
Beinvenu, P., et al., “Antioxidant effects in radioprotection,”Antioxidants in Therapy and Preventive Medicine., 1990, 264, 291-300.
Bottollier-Depois, J.-F., et al., “Assessing exposure to cosmic radiation during long-haul flight,”Radiat. Res., 2000, 153, 526-532.
Coughenour, L.L., et al., “A new device for the rapid measurement of impaired motor function in mice,”Pharmacol. Biochem.&Behav., 1977, 6, 351-353.
Devi, et al., “In vivo radioprotection by ocimum flavonoids: surviva of mice,”Radiat, Res., 1999, 151(1), 74-78.
Emerit, I., et al., “Oxidative stress-related clastogenic factors in plasma for Chernobyl liquidators: protective effects of antioxidant plant phenols, vitamins an oligoelements,”Mutat. Res., 1997, 377(2), 239-246.
Kelloff, G.J., et al., “Progress in cancer chemoprevention: development of diet-derived chemopreventive agents,”J. Nutr., 2000, 130, 467S-471S.
Kennedy, C.W., et al., “Effects of the bowman-birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation andcis-platinum,”Nutr. Canc., 1996, 26, 209-217.
Kim, H., et al., “Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor β signaling pathways,”Am. J. Clin. Nutr., 1998, 68, 1418S-1425S.
Kuo, S.-M., “Dietary flavonoid and cancer prevention: evidence and potential mechanism,”Organogenesis, 1997, 8(1), 47-69.
Landauer, M.R., “Genistein treatment protects mice from ionizing radiation injury,”J. of Applied Toxicology, 2003, 23, 379-385.
Landauer, M.R., et al., “Synthetic trehalose dicorynomycolate (S-TDCM): behavioral effects and radioprotection,”J. Radiat. Res., 1997, 38, 45-54.
Landauer, R., et al., “Protection from lethal irradiation by genistein,”International J. of Toxicology, 2000, 19(6), p. 37.
Liu, R., et al., “Analysis of mechanisms involved in the prevention of γ irradiation-induced apoptosis by hGM-CSF,”Oncogene, 2000, 19, 571-579.
MacPhail, P.C., “Motor activity and screening for neurotoxicity,”J. Am. Coll. of Toxicol., 1989, 8(1), 117-125.
McPherson, C.W., “Reduction ofPseudomonas aeruginosaand coliform bacteria in mouse drinking water following treatment with hydrochloric acid or chlorine,”Lab. Animal Care, 1963, 13, 737-744.
Messina, M.J., “Legumes and soybeans: overview of their nutritional profiles and health effects,”Am. J. Clin. Nutr., 1999, 70(Suppl.), 439S-450S.
Meyer, O.A., et al., “A method for the routine assessment of fore- and hindlimb grip strength of rats and mice,”Neurobehav. Toxicol., 1979, 1, 233-236.
Miernicki, M., et al., “Radioprotective efficacy of 17β-estradiol in mice,”Soc. Neurosci. Abstr., 1990, 16, Abstract No. 433.19, p. 1054.
Parsons, J.L., et al., “interplanetary crew dose rates for the Aug. 1972 solar particle event,”Radiat. Res., 2000, 153, 729-733.
Patt, H.M., et al., “Influence of estrogens on the acute x-irradiation syndrome,”Amer. J. Physiol., 1949, 159, 269-280.
Shimoi, et al., “Radioprotective effect of antioxidative flavonoids in gamma-ray irradiated mice,”Carcinogenesis, 1994, 15(11), 2669-2672.
Takimoto, C.H., “Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer,”Cancer, Epidemiology, Biomarkers&Prevention, 2003, 121213-1221.
Uckun, F.M., et al., “In vivo toxicity, pharmacokinetics, and anticancer activity of genistein linked to recombinant human epidermal growth factor,”Clin. Canc. Res., 1998, 4, 1125-1134.
Van Rijn, J., et al., “Flavonoids as enhancers of X-ray-induced cell damage in hepatoma cells,”Clin. Canc. Res., 1997, 3, 1775-1779.
Wei, H., et al., “Antioxidant and antipromotional effects of the soybean isoflavone genistein(43844),”Proc. Soc. Exp. Biol. Med., 1995, 208, 124-130.
Weiss, J.F., et al., “Radioprotection by antioxidants,”Ann. NY Acad. Sci., 2000, 899, 44-60.
Landauer Michael R.
Seed Thomas Michael
Shapiro Alla
Srinivasan Venkataraman
Takimoto Chris H.
Padmanabhan Sreeni
Ramachandran Umamaheswari
The United States of America as represented by the Department of
Woodcock & Washburn LLP
LandOfFree
Phytoestrogenic isoflavone compositions, their preparation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phytoestrogenic isoflavone compositions, their preparation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phytoestrogenic isoflavone compositions, their preparation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178733